Alzheimer’s disease (AD): emerging investigations

Evidence-based neurology checklist on alzheimer’s disease (ad): emerging investigations: Emerging blood investigations Serum neurofilaments (NFL) Serum S100B Plasma p-tau231 Plasma p-tau181 Serum β-synuclein Emerging cerebrospinal fluid (CSF) investigations Other emerging investigations

Emerging blood investigations

  • Serum neurofilaments (NFL)
  • Serum S100B
  • Plasma p-tau231
  • Plasma p-tau181
  • Serum β-synuclein

Emerging cerebrospinal fluid (CSF) investigations

Other emerging investigations

References

  1. Hort J, O’Brien JT, Gianotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol 2010; 17:1236-1248.
  2. Preische O, Schultz SA, Apel A, et al; Dominantly Inherited Alzheimer Network. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med 2019; 25:277-283.
  3. Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2019; doi: 10.1001/jamaneurol.2019.0765 (Epub ahead of print).
  4. Bellaver B, Ferrari-Souza JP, Uglione da Ros L, et al. Astrocyte biomarkers in Alzheimer disease: a systematic review and meta-analysis. Neurology 2021 (Online ahead of print).
  5. Ashton NJ, Pascoal TA, Karikari TK, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathol 2021; 141:709-724.
  6. And 7 more. Subscribe to see the full list

Related checklists

Loading...